AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0500
+0.1035 (+10.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9465
Open1.0500
Bid1.0500 x 1200
Ask1.1300 x 800
Day's Range0.9600 - 1.0600
52 Week Range0.9050 - 3.7500
Volume626,068
Avg. Volume171,317
Market Cap22.159M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-0.8690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.87
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

    BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. AzurRx expects to receive aggregate gross proceeds of $5.0 million from the offering. The offering is expected to close on or about July 22, 2019, subject to customary closing conditions.

  • GlobeNewswire3 days ago

    AzurRx BioPharma Announces Proposed Public Offering of Common Stock

    H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.  National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager for the offering.

  • Zacks Small Cap Research10 days ago

    AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI

    The effort will examine combination use of MS1819-SD and pancreatic enzyme replacement therapy (PERT) for cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI). This is a subset of CF patients that are suffer from malnutrition and fail to absorb sufficient fat despite taking the maximum dose of PERT therapy. The new study will be conducted at six sites in Hungary with an enrollment target of 28.

  • GlobeNewswire12 days ago

    AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET

    NEW YORK, July 08, 2019 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies.

  • GlobeNewswire12 days ago

    AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency.

  • GlobeNewswirelast month

    AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers

    The inhibitors are a novel, potent and selective group of anti-microbials that have the potential to safely eradicate Helicobacter pylori (H. pylori) bacterial infections that would spare the normal microbiome and would not precipitate antibiotic resistance in off-target bacterial species.

  • How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.2 months ago

    How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Zacks Small Cap Research2 months ago

    AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients

    On May 20th AzurRx BioPharma, Inc. (AZRX) presented secondary endpoint results for its Phase II Chronic Pancreatitis (CP) study, which completed clinical work in June 2018. The update follows topline and primary endpoint results released from the same trial last fall, which found a coefficient of fat absorption of 21.8% statistically significant to a p value of 0.002. The MS1819-SD Phase 2a open-label, dose escalation study was conducted in France, Australia and New Zealand.

  • GlobeNewswire2 months ago

    AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has reached its enrollment target of 30-35 patients in its ongoing Phase II OPTION study of MS1819-SD for exocrine pancreatic insufficiency in patients with cystic fibrosis (CF).  The Company has completed screening activities for enrollment of the study, which is taking place across investigative sites in North America and Poland.

  • GlobeNewswire2 months ago

    AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today released new data for its lead development candidate MS1819-SD at the 2019 Digestive Disease Week (DDW) Conference. The presentation entitled “Results from a Phase II Study of MS1819, a Recombinant Lipase for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Chronic Pancreatitis” was delivered by Dr. Nam Q. Nguyen, et al., on May 20, 2019.

  • GlobeNewswire3 months ago

    AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has now surpassed the 50% enrollment target in its ongoing Phase II OPTION study of MS1819-SD for exocrine pancreatic insufficiency in patients with cystic fibrosis (CF). The Phase II multi-center OPTION study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine pancreatic enzyme replacement therapy (PERT) standard of care for exocrine pancreatic insufficiency in CF patients.  Planned enrollment is expected to include approximately 30 CF patients, with top-line results expected in Summer 2019.

  • Zacks Small Cap Research3 months ago

    AZRX: CF Study Up and Enrolling; Target to $8

    Highlights for the year and to date include participation in investment conferences, the addition of Dr. James Pennington as CMO, presentation of favorable trial data from chronic pancreatitis patients, the launch of the cystic fibrosis trial, and acquisition of rights from Protea and Mayoly. Research and development expenses were up 108% compared to the prior year period.

  • GlobeNewswire4 months ago

    Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights

    AzurRx materially expands global commercial rights, with full development control of MS1819 programMayoly retains certain commercial rights, while obtaining a sizeable equity.

  • GlobeNewswire4 months ago

    AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference

    NEW YORK, March 18, 2019 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies.

  • GlobeNewswire4 months ago

    AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)

    The company’s management will provide an overview of the Company's business during the live presentation and will be participating in one-on-one meetings with investors who are registered to attend the conference.

  • GlobeNewswire4 months ago

    AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced a poster presentation at the 2019 Annual Meeting of the Americas Hepato-Pancreato-Biliary Association being held in Miami, Florida on March 20-24, 2019. The poster will focus on data from its Phase II study of MS1819-SD in patients with chronic pancreatitis that was completed in 2018. “Our oral MS1819-SD therapy is a novel treatment for patients with gastrointestinal disorders and, based on these encouraging and positive data, we are continuing to progress our clinical trials.  We are currently enrolling patients in our cystic fibrosis study, which has 10 U.S. sites initiated to date with the rest expected to be up and running in the next four weeks.

  • GlobeNewswire5 months ago

    AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today provided a clinical development and strategic corporate update.

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.6 months ago

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    If you want to know who really controls AzurRx BioPharma, Inc. (NASDAQ:AZRX), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...

  • GlobeNewswire7 months ago

    AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has initiated the Company's Phase II OPTION study to investigate MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The Phase II multi-center study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine enzyme replacement therapy standard of care.  Planned enrollment is expected to include approximately 30 CF patients, with study completion anticipated in 2019.

  • GlobeNewswire7 months ago

    AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced that it is acquiring royalty and milestone obligations to its lead drug candidate MS1819-SD, a recombinant lipase for exocrine pancreatic insufficiency, from Protea Biosciences Group (“Protea”), who initiated Chapter 11 proceedings in December 2017. Following an auction held on November 27, 2018, AzurRx emerged as the successful bidder for contractual rights to milestone and royalty payments under a Stock Purchase and Sale Agreement previously executed by AzurRx and Protea.

  • Zacks Small Cap Research7 months ago

    AZRX: 3Q:18 Financial and Operational Summary

    Highlights for the period and to date include participation in investment conferences, presentation of favorable trial data, acceptance of a new IND and a nod of approval from the Therapeutics Development Network for their cystic fibrosis trial protocol. Financial results for the quarter reflect the interim between the chronic pancreatitis study and the cystic fibrosis study and show an expected dip in cash burn. Research and development expenses were up 21% compared to the prior year period as AzurRx established its R&D function in the United States and recognized related costs, but were down sequentially, representing a break between the CP and CF studies.

  • GlobeNewswire7 months ago

    AzurRx BioPharma to Present at Upcoming Investor Conferences

    BROOKLYN, N.Y., Dec. 04, 2018 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.

  • GlobeNewswire9 months ago

    AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI

    On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019  NEW YORK, Nov. 01, 2018 -- AzurRx BioPharma, Inc..

  • Zacks Small Cap Research10 months ago

    AZRX: Final Results from Phase II EPI Trial

    Other endpoints were also positive, including Bristol stool scale, number of daily evacuations and weight of stool, which were consistent with the CFA results. CMO Dr. Pennington was pleased at the high level of statistical significance of the results and announced his expectation that the Phase IIb portion of the trial in cystic fibrosis (CF) will begin later in 2018. This compares to the dose response of just over 16% that was achieved in the Phase 1/2a FLIP110 study.